Moderna (NASDAQ:MRNA) Reaches New 52-Week High – Here’s Why

Moderna, Inc. (NASDAQ:MRNA)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $60.35 and last traded at $60.0850, with a volume of 4629830 shares. The stock had previously closed at $55.40.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: FDA advisers unanimously backed Moderna’s investigational flu vaccine, saying its benefits outweigh its risks in older adults, a major regulatory milestone that could support future approval and commercialization. Article: US FDA advisers vote in favor of Moderna’s flu vaccine
• Positive Sentiment: FDA briefing materials were more constructive than investors feared, easing approval concerns and helping extend Moderna’s recent stock momentum. Article: MRNA Stock Jumps as FDA Briefing Docs Ease Flu Shot Approval Concerns
• Positive Sentiment: Moderna also announced that the FDA advisory committee voted unanimously in favor of the benefit-risk profile for mRNA-1010, with the PDUFA decision date still set for August 5, 2026. Article: Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010
• Neutral Sentiment: Investors are also waiting for Moderna’s Science Day on June 25, which could provide more pipeline details and another near-term catalyst. Article: Moderna to Host Investor Event – Science Day
• Negative Sentiment: One minor overhang is insider selling: President Stephen Hoge sold shares under a pre-arranged trading plan, which can still make some investors cautious despite not necessarily signaling weak fundamentals. Article: Moderna (NASDAQ:MRNA) President Sells $2,739,870.32 in Stock

Analyst Upgrades and Downgrades

MRNA has been the subject of several recent research reports. Morgan Stanley set a $33.00 price objective on Moderna in a report on Friday, May 1st. Barclays increased their target price on Moderna from $25.00 to $48.00 and gave the stock an “equal weight” rating in a report on Thursday, April 2nd. The Goldman Sachs Group lifted their price target on shares of Moderna from $43.00 to $49.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. Bank of America boosted their price target on shares of Moderna from $32.00 to $34.00 and gave the company an “underperform” rating in a research note on Monday, June 8th. Finally, Royal Bank Of Canada upped their price objective on shares of Moderna from $35.00 to $38.00 and gave the stock a “sector perform” rating in a report on Monday, May 4th. Two research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and five have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $36.60.

Moderna Price Performance

The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. The business has a fifty day simple moving average of $50.33 and a 200 day simple moving average of $45.10. The stock has a market capitalization of $25.38 billion, a P/E ratio of -7.85 and a beta of 1.05.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing the consensus estimate of ($3.02) by ($0.38). Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The company had revenue of $389.00 million during the quarter, compared to analysts’ expectations of $236.37 million. During the same period last year, the company earned ($2.52) earnings per share. The business’s revenue for the quarter was up 260.2% compared to the same quarter last year. On average, analysts expect that Moderna, Inc. will post -6.51 earnings per share for the current year.

Insider Buying and Selling

In other news, President Stephen Hoge sold 53,336 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the sale, the president owned 1,483,848 shares in the company, valued at $76,225,271.76. This represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Noubar Afeyan sold 9,263 shares of the stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $46.84, for a total transaction of $433,878.92. Following the completion of the sale, the director owned 3,924 shares of the company’s stock, valued at approximately $183,800.16. This represents a 70.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 125,088 shares of company stock valued at $6,193,713. 10.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Moderna

A number of institutional investors have recently added to or reduced their stakes in the company. MUFG Securities EMEA plc bought a new position in shares of Moderna during the 2nd quarter worth approximately $28,000. Flagship Harbor Advisors LLC bought a new position in shares of Moderna in the fourth quarter valued at approximately $31,000. Canton Hathaway LLC bought a new position in shares of Moderna in the first quarter valued at approximately $31,000. Ameriflex Group Inc. grew its holdings in shares of Moderna by 3,775.0% in the third quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock valued at $32,000 after acquiring an additional 1,208 shares in the last quarter. Finally, Cromwell Holdings LLC increased its position in shares of Moderna by 39.7% during the fourth quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock valued at $35,000 after acquiring an additional 341 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.